age \< 18 pregnant allergic to experimental drugs and patients have the following conditions: * hypercholesterolemia * hypertriglyceridemia * liver disease * renal disease * sjögren syndrome * pregnancy * lactation * depressive disorder * body mass index less than 18 points or higher than 25 points * contraindications for hormonal contraception or intrauterine device. * autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation * patients receiving anti-hcv treatment * permanent blindness in one eye * history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery * the competent physician considered it inappropriate to participate in the study previous history of deep vein thrombosis or pulmonary embolism in the last 12 months. * patients with postmenopausal vaginal bleeding with no defined etiology. * patients with breast cancer who need to use tamoxifen for this neoplasm * another synchronous neoplasm that requires systemic treatment patients with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization) a history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study * patients participating in other protocols with experimental drugs. * patients with oral food difficulties. * patients who underwent major recent surgery less than 4 weeks previously. * patients receiving chemotherapy or other oncologic therapy for less than 3 weeks

age \< 18 pregnant allergic to experimental drugs and patients have the following conditions: * hypercholesterolemia * hypertriglyceridemia * liver disease * renal disease * sjögren syndrome * pregnancy * lactation * depressive disorder * body mass index less than 18 points or higher than 25 points * contraindications for hormonal contraception or intrauterine device. * autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation * patients receiving anti-hcv treatment * permanent blindness in one eye * history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery * the competent physician considered it inappropriate to participate in the study previous history of deep vein thrombosis or pulmonary embolism in the last 12 months. * patients with postmenopausal vaginal bleeding with no defined etiology. * patients with breast cancer who need to use tamoxifen for this neoplasm * another synchronous neoplasm that requires systemic treatment patients with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization) a history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study * patients participating in other protocols with experimental drugs. * patients with oral food difficulties. * patients who underwent major recent surgery less than 4 weeks previously. * patients receiving chemotherapy or other oncologic therapy for less than 3 weeks

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: - hypercholesterolemia - hypertriglyceridemia - liver disease - renal disease - sjögren syndrome - pregnancy - lactation - depressive disorder - body mass index less than 18 points or higher than 25 points - contraindications for hormonal contraception or intrauterine device. - autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation - patients receiving anti-hcv treatment - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery - the competent physician considered it inappropriate to participate in the study previous history of deep vein thrombosis or pulmonary embolism in the last 12 months. - patients with postmenopausal vaginal bleeding with no defined etiology. - patients with breast cancer who need to use tamoxifen for this neoplasm - another synchronous neoplasm that requires systemic treatment patients with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization) a history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study - patients participating in other protocols with experimental drugs. - patients with oral food difficulties. - patients who underwent major recent surgery less than 4 weeks previously. - patients receiving chemotherapy or other oncologic therapy for less than 3 weeks

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: - hypercholesterolemia - hypertriglyceridemia - liver disease - renal disease - sjögren syndrome - pregnancy - lactation - depressive disorder - body mass index less than 18 points or higher than 25 points - contraindications for hormonal contraception or intrauterine device. - autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation - patients receiving anti-hcv treatment - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery - the competent physician considered it inappropriate to participate in the study previous history of deep vein thrombosis or pulmonary embolism in the last 12 months. - patients with postmenopausal vaginal bleeding with no defined etiology. - patients with breast cancer who need to use tamoxifen for this neoplasm - another synchronous neoplasm that requires systemic treatment patients with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization) a history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study - patients participating in other protocols with experimental drugs. - patients with oral food difficulties. - patients who underwent major recent surgery less than 4 weeks previously. - patients receiving chemotherapy or other oncologic therapy for less than 3 weeks